Olof Grip

Medicin och livsvetenskap

1. Crohn Disease 100%
2. Inflammatory Bowel Diseases 88%
3. Ulcerative Colitis 83%
4. Monocytes 42%
5. Cohort Studies 35%
6. vedolizumab 21%
7. Atorvastatin 21%
8. Prospective Studies 21%
9. Infliximab 17%
10. Sweden 14%
11. Multicenter Studies 13%
12. Tumor Necrosis Factor-alpha 13%
13. golimumab 12%
14. Hydroxymethylglutaryl-CoA Reductase Inhibitors 12%
15. Macrophages 10%
16. Confidence Intervals 10%
17. Anti-Inflammatory Agents 9%
18. Colectomy 8%
19. Population 8%
20. Chemokine CCL2 8%
21. Inflammation 7%
22. Pharmaceutical Preparations 7%
23. Therapeutics 7%
24. Cytokines 7%
25. Survival 6%
26. Receptors, Tumor Necrosis Factor, Member 25 6%
27. CT-P13 6%
28. Lipopolysaccharides 6%
29. Interleukin-18 Receptors 6%
30. Food 6%
31. PPAR gamma 6%
32. Oxygen Consumption 6%
33. Unsaturated Fatty Acids 6%
34. Registries 5%
35. Chemokines 5%
36. Transforming Growth Factor alpha 5%
37. Epidemiology 5%
38. Odds Ratio 5%
39. Down-Regulation 5%
40. Energy Intake 5%
41. Pravastatin 5%
42. Body Mass Index 5%
43. Chemokine CXCL10 5%
44. Biosimilar Pharmaceuticals 5%
45. Budd-Chiari Syndrome 5%
46. Lymphocytes 5%
47. Diet 5%
48. Incidence 5%
49. Mucous Membrane 5%
50. Scandinavian and Nordic Countries 5%